Anti-a Foot-and-mouth Disease Virus Type O Foot-and-mouth Disease Virus Recombinant Bivalent Peptide Vaccine Research

This thesis consists of review and research parts 1 Review: the introduction of FMDVFoot-and-mouth disease (FMD) is a highly contagious viral disease for cloven-booted animals, such as cattle and pigs. The outbreak of this disease can cause severe economic losses to the agricultural industry worldwide. FMDV shows a high genetic and antigenic variability, which was referred in seven sero-types (O, A, C, Asial , SAT1 , SAT2 and SAT3) and many subtypes (Domingo et al, 1990). The prevention of FMDV infection is mainly by the use of chemically inactivated whole virus vaccines (Borteling and Reeswijk, 1991). Such vaccines can protect animals against homologous and antigenic related viruses (Van Bekkum, 1969). However, chemically inactivated vaccines poses a risk of releasing un-treated live virus during vaccine production or mixed in the inactive vaccines (Barteling and Rreeswijk, 1991). This limitation has led to the search for safer and more effective vaccine.2 Research partThis part consists of three chaptersChapter 1 A recombinant bivalence candidate vaccine against foot-and-mouth disease virus type O and type AIn convention, one type of FMDV vaccine can only protect livestock from the same sero-type of FMDV infection. Sometimes there are above two sero-type of FMDV co-exist in one area. To protect the livestock from FMDV infection, the multi-valance vaccine is needed to vaccinate animals. But the chemically inactivated multi-valance vaccine is still be in the study, obviously the chance of releasing un-treated live virus was doubled by using this vaccine; Because FMDV type 0 and type A are more dangerous than the other five sero-types, they often outbreak in many countries and could result in international trade embargoes, we began the study of recombiant bivalance vaccine against FMDV type A and type O.The amino acid residues 138~160 and 20~41 of VP1 have been proved to be B cell and Tcell epitopes, respectively. Chemically synthetic peptides containing the B cell epitope (a.a.l38~ 160 of VP1) have been shown to induce virus-neutralizing antibodies. In order to create a new two-valance vaccine to FMDV type O and type A, we chemically synthesized the epitopes of VPlof FMDV type A and legated them into a tandem sequence(138~160—21—40—138—160), also synthesized the epitopes of VP1 of FMDV type O and legated them into a tandem sequence (140~ 161—20~41 —141~160), the two DNA fragments were legated by bovine IgG heavy chain constant region gene, and then was inserted into the expression vector pTrcHis to construct a prokaryotic recombinant expression vector pTH-OAl.